Drug Trial Radar · NCT03980938
Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease
Last checked: Nov 19, 2026Latest source record: Apr 6, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
15
Actual
Start
Jul 8, 2019
Primary completion
Oct 15, 2020
Study completion Oct 15, 2020
Sponsor
- Lead sponsor
- EIP Pharma IncIndustry
- Sponsor type
- Industry
- Collaborators
- Voisin Consulting, Inc.
- First posted
- Jun 10, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 30 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a double-blind, placebo-controlled 2-period 10-week treatment within-subject crossover study of neflamapimod in early-stage Huntington disease (HD). The primary objective is to determine whether neflamapimod can reverse hippocampal dysfunction in patients with early-stage HD, as assessed by the virtual water-maze-test for evaluating spatial learning and selected tests on the Cambridge Neuropsychological Test Automated Battery (CANTAB).
Conditions
- Huntington Disease
Interventions
neflamapimodDrug
40 mg neflamapimod capsule
PlaceboOther
matching placebo capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Latency During the Learning Phase of Virtual Morris Water Maze Test (vMWM)Time frame: Baseline and 10 Weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
John Van Geest Centre for Brain Repair
Cambridge, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.